SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1182 participants.
Also called NCT07944066
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,182 participants
- Registry
-
NCT07944066
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07944066. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-10 (actual); primary completion 2031-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
- Acronym
- SAVE-AS
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Samsung Medical Center
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct07944066- Content hash
587ffe2bae07a9413c21948221ac54a70d673aca76be702bebfc96cfbcc9dace